Skip to main content

Advertisement

Table 4 Treatment of breast events.

From: Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Outcome Studies Participants Risk Ratio (M-H, Fixed, 95% CI), I2
Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)    
Treatment of breast events    
   • at 3 months Saltzstein 2005 90 0.38 (0.25, 0.58), -
Tamoxifen (10 mg daily) versus radiotherapy    
Treatment of gynecomastia/breast pain/or both    
   • after 9 months Perdona 2005 35 0.21 (0.05, 0.83), -